LINDA JACKSON: Open Payments
NPI 1376071092 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,545 in 160 payments from 16 companies in 2025. Trend: 2023 $2,593 · 2024 $3,147 · 2025 $3,545
Food & beverage: $3,313Education: $232
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 38 | $943 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $476 |
| Neurocrine BioSciences, Inc. | 17 | $463 |
| ABBVIE INC. | 26 | $423 |
| E.R. Squibb & Sons, L.L.C. | 18 | $388 |
| Otsuka America Pharmaceutical, Inc. | 15 | $315 |
| Janssen Pharmaceuticals, Inc | 9 | $136 |
| Vanda Pharmaceuticals Inc. | 3 | $94 |
| Lundbeck LLC | 4 | $75 |
| Alkermes, Inc. | 2 | $50 |
Products named: UZEDY, CAPLYTA, INGREZZA, VRAYLAR, COBENFY, REXULTI, AUSTEDO XR, FANAPT.
Industry payments across CA — which companies pay providers there.
